TerminatedEUCTR 2007-001097-90

A one-year multinational, multi-centre, randomised, double-blind, parallel-group, fixed-dose, bifeprunox study combining a 12 week placebo-controlled, quetiapine-referenced phase with a 12-month qu...

This historical record does not confirm current site availability.

Historical research recordBulgaria + GreeceSchizophrenia

The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Bulgaria · Greece
Study phase: Phase 3

Get this study by email

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed

Recruitment status: Terminated
Enrollment listed in the registry: 450
Sponsor: H. Lundbeck A/S
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Drug
Study phase: Phase 3
Locations: Bulgaria, Greece
Age range: Not clearly listed
Official registry ID: EUCTR 2007-001097-90
Official title: Show the full official title
A one-year multinational, multi-centre, randomised, double-blind, parallel-group, fixed-dose, bifeprunox study combining a 12 week placebo-controlled, quetiapine-referenced phase with a 12-month qu...

Recruitment & locations

Terminated

Bulgaria · Greece

Registry details

Historical country statuses

Bulgaria — Prematurely Ended
Greece — Prematurely Ended

Interested in joining this study?

FAQ

Questions about this study

Who is behind this study?

The study sponsor is H. Lundbeck A/S.

Is this study still recruiting?

The historical registry lists this study as terminated.

Want to explore more studies?

Explore studies